Morgan Stanley maintains Ultragenyx Pharmaceutical at Equal-Weight, raises price target to $22 from $20

What happened

Morgan Stanley kept its Equal-Weight rating on Ultragenyx Pharmaceutical and raised its price target to $22 from $20. The revised target is a 10.0% increase and implies 32.3% upside from the November 3 closing price of $16.63.

Confirmed

Global impact / market context

The higher target signals Morgan Stanley sees more potential value in the shares, but the unchanged Equal-Weight rating indicates it did not change its overall stance. If investors respond by buying, that could support the share price; the article reports no market reaction.

Analyst inference

Recent analyst targets in the article range from $16 to $22, while the November 3 close was $16.63. This spread shows differing views on the shares’ value, and the $22 target sits at the top of that reported range.

Confirmed

What to watch

1. Compare later analyst ratings and targets with Morgan Stanley’s $22 target to see whether other firms move toward it or continue to differ. Analyst inference
2. Watch for new company information that could change analysts’ expectations and lead them to revise their price targets or ratings. Analyst inference
3. Track the share price against the November 3 close of $16.63; the stated 32.3% upside is based on that reference price, not a guaranteed return. Confirmed

Evidence

• Original source link unavailable